LLY US5324571083

Report

Delayed Nyse - 12/03 04:10:00 pm
245.58	USD		-0.93%

12/03	FDA adds strict safety warnings on arthritis drugs from Pfizer, AbbVie and Lilly	RE
12/03	Eli Lilly, AbCellera Land FDA's Expanded Emergency Use Approval for COVID-19 Antibody Therapy for Patients Younger Than 12 Years Old	MT
12/03	Eli Lilly Gets FDA's Expanded Emergency Use Approval for Antibody Therapy to Treat COVID-19 Patients Younger Than 12 Years Old	MT

Company

Business Summary

Eli Lilly and Company is a drug manufacturing company. The Company discover, develop, manufacture, and market products in a human pharmaceutical product segment. The Companyâ€™s products include Diabetes and other endocrinology products, including Baqsimi, Basaglar, Forteo, Humalog, Humatrope, Humulin, Jardiance, Trajenta and Trulicity. Its Immunology products include Olumiant and Taltz. Its Neuroscience products include Cymbalta, Emgality, Reyvow, Strattera and Zyprexa. Its Oncology products include Alimta, Cyramza, Erbitux and Verzenio. Other product includes Cialis, for the tratment of erectile dysfunction and benign prostatic hyperplasia. The Company manufacture and distribute its products through facilities in the United States, Puerto Rico, and 8 other countries. Its products are sold in approximately 120 countries.

Number of employees : 35 000 people.

Sales per Business

	2019		2020		Delta
Pharmaceutical Products	22 319.50	100%	24 539.80	100%	+9.95%
USD in Million

Sales per region

	2020
United States	14 229.30	58%
Europe	4 187.70	17.1%
Japan	2 583.10	10.5%
Other Foreign Countries	2 422.70	9.9%
China	1 116.90	4.6%
USD in Million

Managers

Name	Title	Age	Since
David Ricks	Chairman, President & Chief Executive Officer	52	2017
Anat Ashkenazi	Chief Financial Officer & Senior Vice President	47	2021
Timothy Garnett	Chief Medical Officer & VP-Global Medical	-	1998
Daniel Skovronsky	Chief Scientific Officer & Senior Vice President	46	-
Diogo Rau	Senior VP, Chief Information & Digital Officer	-	2021
Alonzo Weems	Senior VP, Chief ethics & Compliance Officer	-	2021
Jon Erik Fyrwald	Independent Director	62	2005
Michael L. Eskew	Independent Director	70	2008
Ralph Alvarez	Independent Director	65	2009
Katherine Baicker, Dr.	Independent Director	48	2011

Members of the board

Name	Title	Age	Since
David Ricks	Chairman, President & Chief Executive Officer	52	2017
Jon Erik Fyrwald	Independent Director	62	2005
Michael L. Eskew	Independent Director	70	2008
Ralph Alvarez	Independent Director	65	2009
Katherine Baicker, Dr.	Independent Director	48	2011
William G. Kaelin, Dr.	Independent Director	62	2012
Marschall S. Runge, Dr.	Independent Director	65	2013
Jackson Peter Tai	Independent Director	69	2013
Juan Luciano	Lead Independent Director	58	2019
Jamere Jackson	Independent Director	51	2016

Equities

	Vote	Quantity	Free-Float		Company-owned shares		Total Float
Stock A	1	957,055,393	955,141,904	99.8%	463,000	0.0%	99.8%

Shareholders

Name	Equities	%
Capital Research & Management Co.	109,033,091	11.4%
Lilly Endowment, Inc.	107,853,610	11.3%
The Vanguard Group, Inc.	65,601,890	6.86%
PNC Bank, NA (Investment Management)	52,105,187	5.45%
The PNC Financial Services Group, Inc.	52,012,151	5.44%
SSgA Funds Management, Inc.	33,115,881	3.46%
PRIMECAP Management Co.	32,700,986	3.42%
T. Rowe Price Associates, Inc. (Investment Management)	30,256,081	3.16%
Wellington Management Co. LLP	28,382,066	2.97%
Fidelity Management & Research Co. LLC	26,298,542	2.75%

Holdings

Name	Equities	%	Valuation
DICERNA PHARMACEUTICALS, INC. (DRNA)	5,414,185	6.97%	112,669,190 USD
IMMUNOCORE HOLDINGS PLC	2,548,145	6.25%	98,154,545 USD
AVIDITY BIOSCIENCES, INC. (RNA)	2,319,396	4.95%	52,186,410 USD
PRECISION BIOSCIENCES, INC. (DTIL)	3,762,190	6.31%	35,703,183 USD
PROQR THERAPEUTICS N.V. (PRQR)	3,989,976	6.23%	30,802,615 USD
NEXTCURE, INC. (NXTC)	2,088,859	7.57%	17,170,421 USD
SIGILON THERAPEUTICS, INC. (SGTX)	2,744,443	8.56%	14,792,548 USD
LEAP THERAPEUTICS, INC. (LPTX)	1,819,758	2.09%	5,077,125 USD
AC IMMUNE SA (ACIU)	0	0.0000%